Marathon Pharma hits pause on $89K drug after price criticism
Note: This section contains information in English only.
Tue, 14 Feb 2017 06:52:55 GMT
Source: Dukascopy Bank SA
Marathon Pharmaceuticals delayed the launch of the muscular dystrophy drug after criticism of its $89K-per-year price, including from two members of Congress.
For further information regarding potential cooperation, please call us or make callback request.
To learn more about Dukascopy Bank Binary Options
/ Forex trading platform, SWFX and other trading related information, please call us or make callback request.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information, please call us or make callback request.
To learn more about Business Introducer and other trading related information, please call us or make callback request.
For further information regarding potential cooperation, please call us or make callback request.